Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Neurology & Psychiatry
Filter     Order     Display # 
Date Item Title
15 Mar 2006 Pain Therapeutics Announces Data Presentation at American Pain Society Meeting Supporting Development of Oxytrex(TM)
14 Mar 2006 Dynogen Initiates Phase II Trial of DDP225 for Treatment of Chronic Functional Vomiting
14 Mar 2006 Avicena Announces Promising Phase II Results From Parkinson's Disease Trial
14 Mar 2006 XenoPort Initiates Phase 3 Clinical Program for XP13512 as a Treatment for Restless Legs Syndrome
14 Mar 2006 Headline Results From Chant Safety and Tolerability Study In Intracerebral Hemorrhage (Ich) Show NXY-059 Achieved Key Endpoints
14 Mar 2006 NMT Medical's MIST Study Indicates That Closing a PFO Has an Effect on Migraine.
13 Mar 2006 Myriad Genetics' Phase 2 Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
11 Mar 2006 MIV Therapeutics Subsidiary, SagaX Inc., Accelerates Development of Surgical Stroke Prevention Device Towards Commercialization
10 Mar 2006 FDA Declares Daytrana™ NDA Resubmission To Be Complete Class I Response
09 Mar 2006 StemCells, Inc. Receives IRB Approval From Oregon Health & Science University To Begin Phase I Clinical Trial In Batten Disease
09 Mar 2006 Repligen Initiates Phase 2 Clinical Trial of RG2417 for Bipolar Depression
09 Mar 2006 Corgentech Phase 2 Trial of ALGRX 4975 Meets Primary Endpoint of Decreased Pain for Tendonitis Patients
09 Mar 2006 FDA Advisory Committee Unanimously Recommends Reintroduction Of Tysabri® For The Treatment Of Relapsing Forms Of Multiple Sclerosis
08 Mar 2006 AC Immune identifies Clinical Lead Compounds for Alzheimer’s Disease Treatment.
08 Mar 2006 Micrus Endovascular Receives Approval to Sell Neurovascular Stent in Europe; First Approved Product From Micrus and BIOTRONIK AG Agreement
08 Mar 2006 Neurocrine Biosciences Announces Results of The Phase II Study in Multiple Sclerosis
08 Mar 2006 Bioms Medical’s Mbp8298 Shows Five-Year Delay Of Disease Progression In Patients With Multiple Sclerosis
07 Mar 2006 Results of phase-III clinical studies of an anti-Parkinson's disease drug Istradefylline/KW-6002 conducted overseas
07 Mar 2006 IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
07 Mar 2006 Quigley Submits Investigational New Drug Application to the FDA for Its QR-333 Diabetic Peripheral Neuropathy Compound; Filing Allows Quigley to Begin Human Clinical Trials Following a 30-Day Review Period
07 Mar 2006 Stem Cell Therapeutics Corp. Announces Interim Preclinical Data and Acceptance to Present at the European Stroke Conference
06 Mar 2006 Cortex Reports Positive Results with CX717 on the Primary Outcome Measure in Adult ADHD Study; Conference Call Scheduled for 10:00 AM EST on March 8, 2006
06 Mar 2006 Tectin™ Phase IIB/III Interim Analysis
04 Mar 2006 Acorda Therapeutics(R) Announces Completion of Enrollment in Fampridine-SR Clinical Trial in Multiple Sclerosis and Expansion of Sales Force for Zanaflex Capsules(TM)
03 Mar 2006 Inflazyme and Helicon Initiate the Phase IIa Clinical Trial with IPL455,903 in Age Associated Memory Impairment
03 Mar 2006 First Patient Enrolled in St. Jude Medical's Migraine Headache Study; Clinical Trial to Explore Link between Common Heart Defect and Migraine Headaches
02 Mar 2006 BioDelivery Sciences Receives Non-Approvable Notification from FDA on Emezine®
02 Mar 2006 Medivation Receives Fda Comments On Huntington’s Disease Ind
02 Mar 2006 Neupro® Receives Approvable Letter from FDA for Early Parkinson's Disease in USA
02 Mar 2006 Tysabri® Two-Year Phase Iii Multiple Sclerosis Clinical Trial Results And Safety Evaluation Published In New England Journal Of Medicine
01 Mar 2006 Allon Therapeutics' AL-208 product successful in Phase I clinical trial
28 Feb 2006 Memory Pharmaceuticals Expands Roche Nicotinic Alpha-7 Alliance
28 Feb 2006 Positive results published for D-Pharm's DP-VPA in epilepsy.
28 Feb 2006 U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder
28 Feb 2006 TorreyPines Therapeutics Initiates Second Phase 1 Study for NGX267, A Selective M1 Agonist for Treatment of Alzheimer’s Disease
27 Feb 2006 Cipralex® - new data supports the superiority of Cipralex® compared to Paxil®/Seroxat®
27 Feb 2006 MediciNova Announces Completion of Enrollment in a Phase II/III Generalized Anxiety Disorder Trial With MN-305
25 Feb 2006 Caraco Pharmaceutical Laboratories Ltd. Announces FDA Approval to Market Fluvoxamine Maleate Tablets
24 Feb 2006 Boehringer Ingelheim receives recommendation from EU scientific committee for Sifrol®/ Mirapexin®(pramipexole) for the treatment of Restless Legs Syndrome (RLS)
24 Feb 2006 BioSystems International Announces Collaboration Agreement with AstraZeneca
24 Feb 2006 Positive Preclinical Efficacy Data with Alzheimer's Disease Lead Product AZD-103 Presented at Keystone Symposia
23 Feb 2006 Study finds that that Xyrem® (sodium oxybate) relieves pain in patients with fibromyalgia
23 Feb 2006 Javelin presents intranasal morphine safety and efficacy data at the American Academy of Pain Medicine
23 Feb 2006 Berlex Files Application for Use of Betaseron in Patients with a First Clinical Episode Suggestive of MS
22 Feb 2006 Valeant Pharmaceuticals Receives FDA Approval of Less-Restrictive Labeling for Tasmar(R)
22 Feb 2006 Cadence Pharmaceuticals Announces Acquisition of Second Phase III Product and $60.8 Million Financing
21 Feb 2006 Corgentech's Pivotal Phase 3 Trial of ALGRX 3268 Demonstrates Significant Pain Relief in Children Versus Placebo
21 Feb 2006 Memory Pharmaceuticals Announces Positive Preliminary Phase 1 Cognitive Data for MEM 3454
18 Feb 2006 FibroGen Reports FG-4539, HIF-PH Inhibitor, Is Neuroprotective and Significantly Reduces Brain Tissue Damage in Preclinical Model of Ischemic Stroke
17 Feb 2006 ORADUR™ Technology Milestone: Remoxy™ (ORADUR-based oxycodone) Receives Special Protocol Assessment and Commences Pivotal Phase III
 
<< Start < Prev 31 32 33 Next > End >>
Results 1501 - 1550 of 1619

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics